Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natco's biosimilars entry plan lifts stock

This article was originally published in Scrip

Executive Summary

Shares of Natco Pharma spurted on Indian bourses after the company announced plans to enter the biosimilars segment, via an exclusive pact with Chemo Sa Lugano of Switzerland.

You may also be interested in...



Natco CEO On Dynamics In The HCV Market

Nexavar compulsory license holder Natco Pharma is counted among the leading players in the Indian oncology market and now looks to be aiming for an encore in the hepatitis C segment. Natco vice chair and CEO Rajeev Nannapaneni talks to Scrip of the large patient numbers on HCV therapy and outlines a potential market "split" in certain rest of the world (RoW) territories with the arrival of Gilead's Epclusa.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

India-China Tango: Can Gland Sustain Listing Luster?

Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?

Topics

Related Companies

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel